Raymond James Financial Inc. Purchases New Shares in TransMedics Group, Inc. (NASDAQ:TMDX)

Raymond James Financial Inc. purchased a new position in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 61,671 shares of the company's stock, valued at approximately $3,845,000. Raymond James Financial Inc. owned 0.18% of TransMedics Group as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in TMDX. Vanguard Group Inc. grew its position in TransMedics Group by 1.1% during the fourth quarter. Vanguard Group Inc. now owns 3,635,919 shares of the company's stock valued at $226,700,000 after buying an additional 40,860 shares during the period. FIL Ltd grew its position in TransMedics Group by 28.0% during the fourth quarter. FIL Ltd now owns 1,000,358 shares of the company's stock valued at $62,372,000 after buying an additional 218,961 shares during the period. Geode Capital Management LLC grew its position in TransMedics Group by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 772,744 shares of the company's stock valued at $48,191,000 after buying an additional 8,954 shares during the period. Emerald Advisers LLC grew its position in TransMedics Group by 146.3% during the fourth quarter. Emerald Advisers LLC now owns 371,711 shares of the company's stock valued at $23,176,000 after buying an additional 220,804 shares during the period. Finally, Norges Bank bought a new stake in TransMedics Group during the fourth quarter valued at approximately $22,861,000. 99.67% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on TMDX shares. Needham & Company LLC reiterated a "hold" rating on shares of TransMedics Group in a research report on Wednesday, April 23rd. Piper Sandler reiterated an "overweight" rating and issued a $105.00 price target (up from $90.00) on shares of TransMedics Group in a research report on Tuesday. Finally, Canaccord Genuity Group reiterated a "buy" rating and issued a $104.00 price target on shares of TransMedics Group in a research report on Tuesday, March 11th. Three equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $124.20.

TransMedics Group Price Performance

TransMedics Group stock traded up $2.24 during mid-day trading on Tuesday, reaching $92.43. 790,522 shares of the company's stock traded hands, compared to its average volume of 1,351,303. The company has a market cap of $3.13 billion, a price-to-earnings ratio of 98.33 and a beta of 2.14. The stock has a 50 day moving average of $74.67 and a two-hundred day moving average of $77.10. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. TransMedics Group, Inc. has a 12-month low of $55.00 and a 12-month high of $177.37.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.